Rongyi Wang, Jing Zheng, Jinxiang Liu, Zhuoqun Li, Chunwei Wang, Kai Zhu, Jinming Zhang, Chunying Wu, Erik F J de Vries, Pengfei Liu, Xu Wang, Yanming Wang
{"title":"In Vivo Quantification of Myelin Injury Following Ischemic Stroke.","authors":"Rongyi Wang, Jing Zheng, Jinxiang Liu, Zhuoqun Li, Chunwei Wang, Kai Zhu, Jinming Zhang, Chunying Wu, Erik F J de Vries, Pengfei Liu, Xu Wang, Yanming Wang","doi":"10.1007/s11307-026-02143-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Ischemic stroke involves substantial myelinated white matter injury, a key cause of long-term neurological deficits. However, conventional MRI often lacks sufficient sensitivity and specificity to detect myelin pathology and resolve lesional heterogeneity, limiting accurate correlation with clinical outcomes and prognostic assessment. To address this limitation, we recently developed a myelin-targeted PET radiotracer, [<sup>11</sup>C]MeDAS, which enables in vivo characterization of myelin integrity with high sensitivity and specificity. To establish its utility in ischemic stroke, we conducted a translational imaging study across species.</p><p><strong>Procedures: </strong>Dynamic [<sup>11</sup>C]MeDAS-PET/CT imaging, incorporating perfusion correction, was performed sequantially in a rodent middle cerebral artery occlusion (MCAO) model, a rhesus monkey with spontaneous ischemic stroke, and a cohort of six patients with acute ischemic stroke.</p><p><strong>Results: </strong>In MCAO rats, tracer uptake was significantly reduced in the lesioned hemisphere (SUV ratio: 0.64 ± 0.08, P < 0.001), closely correlating with histological myelin loss. In the non-human primate, infarcted regions exhibited up to 60% SUV reduction in SUV, while stroke patients demonstrated 26-43% lower uptake in infarct cores. Notably, these reductions persisted after perfusion correction. Furthermore, voxel-level analyses revealed pathological heterogeneity within lesions that appeared homogeneous on MRI.</p><p><strong>Conclusions: </strong>This translational study in rodent model, non-human primates, and human patients demonstrates that [<sup>11</sup>C]MeDAS-PET is a promising molecular imaging approach for assessing tissue alterations following ischemic stroke. These findings warrant further investigation of [<sup>11</sup>C]MeDAS-PET as an imaging marker for ischemic stroke.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-026-02143-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Ischemic stroke involves substantial myelinated white matter injury, a key cause of long-term neurological deficits. However, conventional MRI often lacks sufficient sensitivity and specificity to detect myelin pathology and resolve lesional heterogeneity, limiting accurate correlation with clinical outcomes and prognostic assessment. To address this limitation, we recently developed a myelin-targeted PET radiotracer, [11C]MeDAS, which enables in vivo characterization of myelin integrity with high sensitivity and specificity. To establish its utility in ischemic stroke, we conducted a translational imaging study across species.
Procedures: Dynamic [11C]MeDAS-PET/CT imaging, incorporating perfusion correction, was performed sequantially in a rodent middle cerebral artery occlusion (MCAO) model, a rhesus monkey with spontaneous ischemic stroke, and a cohort of six patients with acute ischemic stroke.
Results: In MCAO rats, tracer uptake was significantly reduced in the lesioned hemisphere (SUV ratio: 0.64 ± 0.08, P < 0.001), closely correlating with histological myelin loss. In the non-human primate, infarcted regions exhibited up to 60% SUV reduction in SUV, while stroke patients demonstrated 26-43% lower uptake in infarct cores. Notably, these reductions persisted after perfusion correction. Furthermore, voxel-level analyses revealed pathological heterogeneity within lesions that appeared homogeneous on MRI.
Conclusions: This translational study in rodent model, non-human primates, and human patients demonstrates that [11C]MeDAS-PET is a promising molecular imaging approach for assessing tissue alterations following ischemic stroke. These findings warrant further investigation of [11C]MeDAS-PET as an imaging marker for ischemic stroke.
期刊介绍:
Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures.
Some areas that are covered are:
Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes.
The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets.
Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display.
Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging.
Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics.
Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations.
Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.